

## Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our [Editorial Policies](#) and the [Editorial Policy Checklist](#).

### Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

n/a Confirmed

- The exact sample size ( $n$ ) for each experimental group/condition, given as a discrete number and unit of measurement
- A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
- The statistical test(s) used AND whether they are one- or two-sided  
*Only common tests should be described solely by name; describe more complex techniques in the Methods section.*
- A description of all covariates tested
- A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
- A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
- For null hypothesis testing, the test statistic (e.g.  $F$ ,  $t$ ,  $r$ ) with confidence intervals, effect sizes, degrees of freedom and  $P$  value noted  
*Give  $P$  values as exact values whenever suitable.*
- For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
- For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
- Estimates of effect sizes (e.g. Cohen's  $d$ , Pearson's  $r$ ), indicating how they were calculated

*Our web collection on [statistics for biologists](#) contains articles on many of the points above.*

### Software and code

Policy information about [availability of computer code](#)

Data collection Python 3.8.15, Micro-Manager 2.0.0, pClamp 11

Data analysis Python 3.8.15, Graphpad Prism 9.0, pClamp 11

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio [guidelines for submitting code & software](#) for further information.

### Data

Policy information about [availability of data](#)

All manuscripts must include a [data availability statement](#). This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our [policy](#)

Due to the quantity of data acquired in total, the data that support the findings of this study are available from the corresponding author on reasonable request. Source data will be provided with the manuscript along with representative datasets.

## Human research participants

Policy information about [studies involving human research participants and Sex and Gender in Research](#).

Reporting on sex and gender	N/A
Population characteristics	N/A
Recruitment	N/A
Ethics oversight	N/A

Note that full information on the approval of the study protocol must also be provided in the manuscript.

## Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

Life sciences  Behavioural & social sciences  Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see [nature.com/documents/nr-reporting-summary-flat.pdf](https://nature.com/documents/nr-reporting-summary-flat.pdf)

## Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size	Sample-size calculations were not performed as the effect size was not known before the study. However, in each case we aimed to exceed typical sample sizes used to perform comparable experiments for validating novel voltage imaging approaches.
Data exclusions	For patch-clamp experiments, recordings were excluded if the recording was not sufficiently stable throughout the duration of the experiment or if the quality of the patch was insufficient to clamp the membrane potential to the necessary voltage with sufficient accuracy. In all cases, only recordings with an access resistance below 35 MΩ were included in subsequent analysis. For current-clamp recordings performed in hippocampal organotypic slices, only cells which were maintained at the original (break-in) resting membrane potential via current injection smaller than 100 pA were included in subsequent analysis.
Replication	All experiments were repeated multiple times from multiple preparations (CHO cells and hippocampal organotypic slices) and multiple (at least two) transfections/ infections in each case, as reported in the Methods section of the manuscript. These experiments had comparable outcomes in all cases.
Randomization	Where possible, different measurements performed on single cells were shuffled, or, where necessary, performed in the same order for each condition. For instance Protocol 1 was routinely the first recording since it was used to confirm the voltage sensitivity of the fluorescence. Fluorescent cells were randomly selected from those that appeared to be in good health (as determined from the transmitted light image), well adhered to the cover slip and were fluorescent. Hippocampal slice cultures were randomly chosen for virus transduction.
Blinding	Data analysis was not performed blindly since the modality used for excitation was apparent in the raw images. However, an automated data analysis pipeline was established by pooling data acquired using all modalities and then used to analyse all data acquired using a particular protocol (without changing any parameters), as outlined in the manuscript.

## Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Materials & experimental systems		Methods	
n/a	Involved in the study	n/a	Involved in the study
<input type="checkbox"/>	<input checked="" type="checkbox"/> Antibodies	<input checked="" type="checkbox"/>	<input type="checkbox"/> ChIP-seq
<input type="checkbox"/>	<input checked="" type="checkbox"/> Eukaryotic cell lines	<input checked="" type="checkbox"/>	<input type="checkbox"/> Flow cytometry
<input checked="" type="checkbox"/>	<input type="checkbox"/> Palaeontology and archaeology	<input checked="" type="checkbox"/>	<input type="checkbox"/> MRI-based neuroimaging
<input type="checkbox"/>	<input checked="" type="checkbox"/> Animals and other organisms		
<input checked="" type="checkbox"/>	<input type="checkbox"/> Clinical data		
<input checked="" type="checkbox"/>	<input type="checkbox"/> Dual use research of concern		

## Antibodies

Antibodies used HSP70 / HSP72 (mouse; Enzo Life Science, ADI-SPA-810-D; lot n°01031912 dilution: 1:400), Cleaved Caspase-3 [Asp175] (rabbit; Cell Signaling, 9661; lot n°47, dilution: 1:250), Anti-mouse-Alexa fluor 647 (Thermofisher Scientific, A21235; lot n°2369432, dilution: 1:500), Anti-rabbit-Alexa fluor 555 (Thermofisher Scientific, A21429; lot n°2354429, dilution: 1:500).

Validation Immunohistochemistry experiments were performed following procedures reported in existing literature, DOI: 10.1152/jn.00275.2016 (dilutions) and DOI: 10.1038/hprot.2006.180 (protocol).

The specificity of antibody labeling was tested by performing a negative control (staining hippocampal organotypic slices which had not been exposed to light from a pulsed, infrared ultrafast source).

## Eukaryotic cell lines

Policy information about [cell lines and Sex and Gender in Research](#)

Cell line source(s)	CHO
Authentication	CHO cells were purchased from Sigma-Aldrich (distributor in Europe for the European Collection of Authenticated Cell Culture (ECACC)).
Mycoplasma contamination	Not tested
Commonly misidentified lines (See <a href="#">ICLAC</a> register)	N/A

## Animals and other research organisms

Policy information about [studies involving animals; ARRIVE guidelines](#) recommended for reporting animal research, and [Sex and Gender in Research](#)

Laboratory animals	Hippocampal organotypic slices were prepared from mice of both sexes (Janvier Labs, C57Bl6J) at postnatal day 8 (P8).
Wild animals	N/A
Reporting on sex	N/A
Field-collected samples	N/A
Ethics oversight	All experimental procedures were conducted in accordance with guidelines from the European Union and institutional guidelines on the care and use of laboratory animals (Council Directive 2010/63/EU of the European Union).

Note that full information on the approval of the study protocol must also be provided in the manuscript.